Biotech & Pharma.T.A, Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A,

BIB 76.73

+1.7%

Nov 17 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jibacoa who wrote (2543)	9/21/2009 2:53:57 PM
From: Jibacoa	Read Replies (2) of 3722

MRNA was up 14.38% at its intraday H and is still up 7.19% at present, with volume of > 711,000 > 1.5x its ADV. bigcharts.marketwatch.com Besides the previously mentioned news on Jun 9, it also had announced on Jun 8 in vivo data from a bladder Ca model demonstrating effective localized delivery of a UsiRNA to a solid tumor,expanding the delivery capabilities of the DiLA2 Platform. It also reported in vivo data demonstrating the ability of its peptide-based nanoparticle technology to significantly improve siRNA delivery efficiency. The integration of the peptide nanoparticle technology with the DiLA2 Platform resulted in 85% knockdown of ApoB messenger RNA while decreasing the overall amount of the DiLA2 delivery vehicle by 45%. The data were presented at the RNA Interference Summit in Frisco. It also presented data demonstrating knockdown of additional hepatocyte targets in rodent models. The DiLA2 liposomes showed 90% knockdown of DGAT2 in mice following a single 2 mg/kg administration and a 75% knockdown of PCSK9 with a single 2 mg/kg dose. Consistent with highly efficient delivery to hepatocytes, which is the basis for MRNA's development pipeline in oncology. DiLA2 is a versatil delivery system, and this Platform will enable effective therapeutic applications of siRNAs in oncology and various other disease indications, according to MRNA's executives. As was also mentioned, on April 2, MRNA announced that it had sold its Manufacturing Business to Par Pharmaceuticals and it was concentrating on its RNAi projects. According to its CEO, Michael French, "that agreement eliminates all of MDRNA's non-RNAi expenses and represents the final step in the plan to create a company solely focused in the research and development of RNAi-based therapeutics." MRNA's ACTAY is $3 but with the Jun 9 spike at $3.55 and MRNA trimming its loss by 75% in the current year, I will put my 'target' at its Dec 2007 H of $4.50 <g> bigcharts.marketwatch.com MRNA's short position increased > 30% in the last month ans is about 4.6x its ADV. Disclosure: I am long MRNA <g> Bernard

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next